SPTX
HealthcareSeaport Therapeutics, Inc. Common Stock
Key Drivers
- Strong Liquidity Position
- Persistent Operating Losses
- Equity Financing Reliance
AIAI Summary
SPTX is a well-funded but binary clinical-execution investment: its cash runway likely carries it to the pivotal BUOY-1 Phase II-B readout in 1H 2027, where convincing GlyphAllo efficacy alongside its favorable next-day safety profile could re-rate the platform, while weak efficacy would sharply impair valuation and raise dilution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity Position
- •Persistent Operating Losses
- •Equity Financing Reliance
SPTX has strong liquidity and low leverage after equity financing, but its no-revenue model, steep losses, and ongoing cash burn make it a high-risk investment.
Price Behavior
Key Price Behavior Insights:
- •Persistent downtrend
- •Support under pressure
- •Recovery resistance
SPTX fell 11% over the last month to $21.39, with sellers in control below resistance, so watch $21.40–$21.80 support for a breakdown or $23.30–$24.10 for recovery confirmation.
Declined over 20% from the $27.84
Sentiment & News
Key News Insights:
- •Positive Phase 1
- •GlyphAllo Focus
- •Investor Engagement
Seaport's positive Phase 1 GlyphAllo driving-simulation data and expanded investor outreach strengthen its post-IPO clinical and market visibility.
The updates may support positive investor sentiment by validating Seaport's lead program and sustaining institutional interest
Similar Companies in Healthcare
Other companies in the same sector with AI ratings